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Summary 
L-selectin expression is regulated in part by membrane-proximal cleavage from the cell surface 
of leukocytes and L-selectin-transfected cells. The downregulation of L-selectin from the surface 
of neutrophils is speculated to be a process involved in the adhesion cascade leading to neutrophil 
recruitment to sites of inflammation. We previously reported that L-selectin is cleaved between 
Lys321 and Ser322 in a region that links the second short consensus repeat (SCR) and the 
transmembrane domain. We demonstrate that replacing this cleavage domain of L-selectin with 
the corresponding region of E-selectin prevents L-selectin shedding, as judged by inhibiting the 
generation of the 68-kD  soluble and 6-kD  transmembrane cleavage products of L-selectin. 
Unexpectedly, we found that point mutations of the cleavage site, as well as mutations of multiple 
conserved amino acids within the cleavage domain, do not significantly affect L-sdectin shedding. 
However,  short deletions of four or five amino acids in the L-selectin cleavage domain inhibit 
L-selectin downregulation. Mutations that appeared to inhibit L-selectin  shedding resulted in 
higher levels of ceU surface expression,  consistent with a lack of apparent proteolysis from the 
cell membrane. One deletion mutant, I327AN332, retains  the native cleavage site yet inhibits 
L-selectin proteolysis as well. Restoring the amino acids deleted between I327 and N332 with 
five alanine residues restores L-selectin proteolysis. Thus, the proteolytic processing of L-selectin 
appears to have a relaxed sequence specificity at the cleavage site, and it may depend on the physical 
length or other secondary structural characteristics  of the cleavage domain. 
T 
he recruitment of leukocytes to sites of inflammation 
involves a highly regulated cascade of events involving 
multiple adhesion proteins and chemokines (1-3).  The na- 
ture of leukocyte migration requires  that these adhesive in- 
teractions be transient in nature. Thus, adhesion molecules 
themselves must be precisely regulated. Adhesion may be rap- 
idly induced by a variety of mechanisms, from qualitative 
changes in receptor activity (4, 5) to quantitative upregula- 
tion of rapidly mobilized pools of receptors (6, 7). However, 
mechanisms that downregulate adhesion molecules or that 
cause de-adhesion are less well characterized.  L-selectin is a 
major leukocyte adhesion protein involved in lymphocyte 
homing to peripheral lymph nodes and in the initial "rolling" 
type interactions of leukocytes with inflamed endothelium 
(8-10).  Endothelial ligands for L-selectin  include sulfated 
mucins, such as GlyCAM-1 and CD34, and the MECA-79 
antigen (11-13). Expression of L-selectin is downmodulated 
in part by an unusual protease activity that causes rapid and 
inducible cleavage  of L-selectin  from  the  cell  membrane 
(14-18). 
The selectin family of adhesion molecules is composed of 
three members, P-selectin, E-selectin, and L-selectin (8). The 
distribution and regulation of each molecule are distinct; 
P-selectin expression is rapidly induced by mobilization of 
intracellular pools to the surface of activated platelets and en- 
dothelial cells, E-selectin is synthesized de novo by cytokine- 
activated endothelium, and L-selectin is constitutively expres- 
sed on the surface of most leukocytes. The structure of each 
molecule is characterized by an NH2-terminal C-type lectin 
domain, an epidermal growth factor (EGF)-homologous do- 
main, a variable number of short consensus repeats (SCRs), 1 
a transmembrane domain, and a COOH-terminal cytoplasmic 
domain. The extracellular domains of the selectins are highly 
conserved with the exception of a short sequence that links 
the last SCR with the transmembrane domain (19-26). Al- 
though soluble forms orE- and P-selectin have been identified, 
the primary mechanism for E- and P-selectin  downregula- 
tion appears to be due to internalization (27, 28). L-selectin 
is the only member that appears to be actively downregu- 
lated from the cell surface through a rapid and inducible 
1  Abbreviations used in this paper: ACE, angiotensin-converting  enzyme; 
3-APP, ~-amyloid precursor protein; EGF, epidermal growth factor; 
L-CDX, L-selectin  cleavage  domain  exchange;  SCR, short  consensus  repeat. 
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factors, L-selectin is rapidly downregulated from the cell surface 
of neutrophils (14). A  soluble form of L-sdectin is present 
(1-2 #g/m1) in normal human serum (29). L-sdectin proteoly- 
sis is unusual in that it is resistant to a variety of protease 
inhibitors (reference  18 and unpublished observations). Al- 
though low levels of exogenous chymotrypsin selectively  cleave 
L-selectin from the surface of neutrophils (30), chymotrypsin 
inhibitors such as N-tosyl-t-phenylalanine chloromethyl ke- 
tone, PMSF,  and aprotinin fail to inhibit L-selectin down- 
regulation. 
We have recently determined that L-selectin is cleaved be- 
tween Lys321 and Ser322 in a short region that links the second 
SCR with the transmembrane domain (15). Cleavage at this 
membrane proximal site of the 74-kD membrane bound form 
of  L-selectin results in the release of a soluble 68-kD L-sdectin 
ectodomain and the formation of a 6-kD L selectin trans- 
membrane peptide (L-STMP) deavage product (15). To better 
characterize the proteolytic event, we have constructed point 
mutants of the cleavage site and of conserved residues within 
the cleavage region. In addition, we have created a chimeric 
molecule that consists of the lectin, EGF, SCK1, SCR2, trans- 
membrane and cytoplasmic domains of L-selectin, and the 
extracellular membrane proximal region of E-selectin.  We 
demonstrate that replacing the L-selectin cleavage domain with 
the corresponding domain from E-selectin effectively inhibits 
downregulation of L-selectin. In addition, a series of short 
deletions (4-5 residues)  within the cleavage domain also in- 
hibits L-selectin shedding. In one deletion, the five deleted 
amino acids were restored with five alanine residues,  which 
in turn restored L-selectin proteolysis. However, point mu- 
tations of the cleavage site and mutations of multiple con- 
served residues  within the cleavage domain do not appear 
to significantly inhibit L-selectin downregulation. These results 
indicate that the proteolytic processing of L-selectin may de- 
pend on the physical length or other secondary structural 
characteristics of the cleavage domain and may not require 
strict sequence  specificity. 
Materials  and Methods 
Construction of  L.Selectin Mutants.  bselectin mutants were gener- 
ated using the Altered Sites oligonucleotide-directed mutagenesis 
system from Promega Biotech (Madison, WI) or by recombinant 
PCR. Mutations in human L-selectin cDNAs were confirmed by 
restriction digest in the plasmid palter (Promega Biotech) and sub- 
cloned into the pCDM8 vector (25). The cDNAs were screened 
for orientation and for the presence of the mutation by direct PCR 
of  bacterial lysates.  Briefly, 1/~1 of a 500-#1 overnight bacterial cul- 
ture was lysed in the presence of 100 ng lysozyme, 0.5% NP-40, 
10 mM Tris, 1 mM EDTA at 94~  for 3 min. Samples were then 
subjected to 25 cycles of PCR using a forward primer specific for 
pCDM8 and a reverse primer specific  for the mutation. PCR prod- 
ucts were analyzed  for the presence of  predicted  bands on 1% agarose 
gels. Clones that yielded the predicted band were sequenced and 
checked for the presence of the engineered mutations and for the 
absence of spontaneous mutations. 
Transfection of COS  Cells.  COS  cells (2.9  x  106  cells per 
cuvette) were mock transfected or transiently transfected with 2 
#g of mutant or wild-type Lselectin by electroporation in the pres- 
ence of DEAE-dextran 01). Each cuvette was diluted into 35 ml 
of complete KPMI, and from this, three 101Ymm tissue culture 
dishes and one 60-ram tissue culture dish were plated. Transfec- 
tants were allowed to recover in nonselective  media supplemented 
with 10% FCS. 
Metabolic Labeling.  One 100-mm plate of  COS transfectants  was 
metabolically  labeled with [35S]methionine  on day 3 or 4 (day I  = 
day of transfection)  as previously  described (15). Briefly,  transfected 
monolayers ('~75-85% confluent) were preincubated with methio- 
nine-free media to deplete  intraceUular  methionine pools. After this 
preincubation, cells  were pulsed with 500 #Ci (5 ml at 100 #Ci/ml) 
of [3SS]methionine for  30-60  min  and  chased with complete 
RPMI medium for 30-120 min as indicated. Cell-free  supernatants 
were harvested, and cellular debris was removed  by centrifugation. 
COS monolayers  were then lysed  in 1% Triton X-100, 20 mM Tris, 
150 mM NaC1, 1 mM PMSF, I mM aprotinin for 30 min at 4~ 
and cell nuclei were removed by centrifugation at 13,000 g for 
30 rain. 
Immunoprecipitation.  Cell lysates  and cell-flee  supernatants  were 
immunoprecipitated as previously  described (15). Cell lysates  were 
precleared with normal rabbit serum (1:200) and protein A-Agarose. 
Cell supernatants were incubated with a 1:200 dilution of a rabbit 
polyclonal  antiserum directed against the ectodomain of I~selectin 
(JK923) or preimmune sera, while precleared cell lysates were in- 
cubated with a 1:200 dilution of an antiserum directed against the 
cytoplasmic domain of bselectin  01(564) or preimmune sera. 
Samples were then incubated with 20 #1 of protein A-Agarose for 
30 min at 4~  while being rotated end-over-end, and they were 
then washed extensively.  After the final wash, material specifically 
bound to the Sepharose was eluted in tricine SDS-PAGE sample 
buffer (Novex, San Diego, CA) and incubated at 90~  for 5 min. 
SDS-PAGEandAutoradiography.  Immunoprecipitated samples 
were run on tricine-SDS polyacrylamide 10-20% gradient gels 
(Novex). Gels were then fixed in 30% methanol, 10% acetic acid, 
1% glycerol, and treated with an autoradiography enhancer (En- 
tisify A/B; DuPont-NEN, Boston, MA), dried in cellophane, and 
exposed to x-ray film (X-OMAT; Eastman Kodak Co., Rochester, 
NY) at  -70~ 
ELISA for Soluble L,  Selectin.  Supernatants were collected from 
COS transfectants on day 3 or 4 posttransfectinn. Cellular debris 
was removed  by centrifugation at 2,000 rpm for 15 min, followed 
by syringe filtration through a 0.2-#m filter. 96-well plates (Max- 
isorp, Nunc, Roskilde,  Denmark) were coated with 100 #1 DREG- 
55 (anti-L-selectin)  at 10 #g/ml and blocked  with 2% BSA. Filtered 
supernatants were serially diluted and applied in 100-#1 aliquots 
to the wells, and the presence of a soluble cleavage product was 
detected using 100 #1 biotinylated DKEG-200 (anti-l.,selectin) at 
1 #g/ml,  a  streptavidin-horseradish peroxidase conjugate, and 
2,2'-azinobis(3-ethylbenzthioazolinesulfonic  acid) substrate per the 
manufacturer's  instructions (Zymed  Labs, Inc., South San Francisco, 
CA). Soluble L-selectin  levels were calculated by a log-logit analy- 
sis curve generated from a serial titration of a known standard of 
purified soluble L-selectin (Bender Medsystems, Vienna, Austria). 
Plates were read on a plate spectrophotometer  (Molecular  Dynamics, 
Sunnyvale, CA) at 405 rim. 
FACS  |  Analysis.  COS transfectants were washed with CaZ+/ 
Mg2+-free PBS containing 2 mM EDTA, followed  by addition of 
2 ml tissue culture grade trypsin-EDTA solution (GIBCO BRL, 
Gaithersburg, MD) for 1-2 min. The trypsin was quenched by the 
addition of  5 ml PBS containing 5% goat serum and 2 mM EDTA. 
The cells were harvested in Ca2+/Mg2+-free PBS containing 5% 
goat serum and 2 mM EDTA by repeated pipeting and washed 
twice with 5% goat serum in PBS. Low doses of trypsin have pre- 
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30 and data not shown). Cells were then incubated with 50/~g/ml 
DREG-56  or DREG-200  for 30 min  at 4~  and washed  twice 
with goat serum/PBS.  Cells were then incubated with a 1:100 di- 
lution  of  phycoerythrin-conjugated  F(ab')z  fragments  of  goat 
anti-mouse IgG (Tago Inc., Burlingame, CA) at 4oC for 30 min 
and washed twice with goat serum/PBS.  Cells were suspended at 
",~1@ cells per ml in 1%  paraformaldehyde/RPMI and were ana- 
lyzed by flow cytometry on a FACScan  |  (Becton Dickinson & Co., 
Mountain View, CA). To confirm surface expression of the L-selectin 
mutants, duplicate plates of COS transfectants were stained in situ 
(without  harvesting)  and  analyzed by fluorescence microscopy. 
Radiochemical  Sequencing.  Radiochemical sequencing was per- 
formed as previously described (15). Briefly, COS cells were trans- 
fected with mutated bselectin cDNA and metabolically  labeled with 
[3SS]methionine. The 6-kD  transmembrane cleavage product was 
immunoprecipitated and the material was subjected to SDS-PAGE 
as described. The sample was then electrotransferred from the gel 
to  a  polyvinyldifluoride membrane  (Immobilon  pSQ; Millipore 
Corp.,  Bedford, MA),  which  was then air dried and exposed to 
x-ray film at  -70~  (Kodak X-OMAT). Once the film was devel- 
oped, it was aligned with the original Immobilon membrane, and 
the area of the membrane corresponding to the location of the 6-kD 
species was excised and subjected to radiochemical sequencing on 
a pulse-liquid protein sequencer (model 477A; Applied Biosystems 
Inc., Foster City, CA). Fractions collected from each degradation 
cycle were analyzed in a  liquid scintillation counter. 
Analysis of  Downregulation  of  Mutated  I~Selectin  Clones.  L-selectin 
mutants were transiently transfected into COS cells on day I  and 
stained with a phycoerythrin-conjugated anti-L-sdectin antibody 
on day 3  or 4.  Cell-free supernatants  were  saved for analysis by 
trapping ELISA. A  100-mm plate was metabolicaUy labeled with 
[3SS]methionine on day 3 or 4 after transfection, and radiolabded 
cellular lysates were immunoprecipitated with JK564 rabbit anti-L- 
selectin cytoplasmic domain serum. Cell-free supematants were im- 
munoprecipitated  with JK923  rabbit anti-L-selectin ectodomain 
serum. Mock transfectants and preimmune sera were used as nega- 
Figure  1.  Exchange of the membrane-proximal region ofbsdectin with 
the corresponding region of E-selectin prevents L-sdectin proteolysis. (A) 
Schematic  representation of the membrane-proximal cleavage domain of 
L-selectin in relation to the whole molecule ($CR, short consensus repeat; 
TM, transmembrane domain; Cy, cytoplasmic domain). The estimated 
molecular weight of the intact molecule and the predicted sizes of the 
bselectin cleavage fragments are indicated. The sequence of the cleavage 
domain of human,  mouse,  and rat bsdectin are aligned, and identical 
residues  within the deavage domain are boxed. The predicted cleavage 
site is indicated with an inverted triangle, and the Pl, P2, P3, Pf, P2', and 
P3' positions of the cleavage site are indicated (36).  The corresponding 
regions of E-sdectin and the DCDX mutant are shown. (B) The IcCDX 
mutant is expressed on the cell surface of COS cell transfactants.  COS 
cells were mock transfected or transfected with L-selectin  of L-CDX eDNA, 
as indicated, and then stained for cell surface expression with D1LEG-200 
mAb and a goat anti-mouse phycoerythrin second-stage  antibody. Cells 
were harvested and analyzed by flow cytometry. Mean fluorescence values 
(MFV) of the whole population and the percentage of cells falling in the 
G1 gate are indicated. (C) The 6-kD transmembrane cleavage product of 
l=selectin is not efficiently produced by L-CDX transfectants.  COS cells 
were transfected with wild-type L-selectin, L-CDX, or mock-transfected 
as indicated. On day 3 after transfcction,  cells were pulse labeled with 
[3sS]methionine for 60 min and chased for 30 rain. Cell lysates were im- 
munoprecipitated with antiserum directed against the cytoplasmic domain 
of L-selectin or with preimmune serum,  as indicated. The upper arrow 
denotes the position of the intact membrane bound bselectin, and the 
lower arrow denotes the position of the 6-kD transmembrane cleavage 
product, as previously described (15). (D) Radiolabeled soluble l~selectin 
is not detectable in the supernatants of L-CDX transfectants.  Cell-free su- 
pematants were harvested From cells transfected  and labeled as described 
above. A  soluble form of L-selectin (arrow) was immunoprecipitated by 
an antiserum against the ectodomain of L-selectin. (E) ELISA analysis for 
soluble I~selectin. Cell-free supematants were harvested  from COS 3 d 
after transfection and serially diluted. Soluble l~selectin present in these 
superuatants was trapped with DREG-55 anti-L-selectin mAb and de- 
tected with biotinylated DREG-200 anti-L-selectin mAb, as described in 
Materials and Methods. Soluble L-selectin levels were quantitated by con- 
structing a standard curve using a purified soluble L-selectin standard. 
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SDS-PAGE and autoradiography.  The presence  of a 6-kD product 
in the lysates, in conjunction with the presence  ofa 68-kD species 
in the supematants, indicated that L-selectin/mutant downregula- 
tion occurred. 
Results 
An L-Se[ectin Chimera Containing the E-Selectin Membrane- 
proximal Region is Resistant to Proteolysis.  We have previously 
shown that L-selectin  is cleaved within a short membrane 
proximal region (cleavage domain) that links the second SCR 
with the transmembrane domain (15). The extracellular  do- 
mains of L-, E-, and P-selectin are highly conserved (19-26); 
however, the short cleavage region of L-selectin  has no ho- 
mologous counterpart in E- or P-sdectin (Fig. 1 A). L-selectin 
is the only member of the family that appears to be actively 
regulated through a rapid and inducible cleavage event from 
the cell surface (14, 16, 27, 28). To determine if the cleavage 
domain is critical for L-selectin proteolysis,  a chimeric mole- 
cule termed L-selectin  cleavage domain exchange (L-CDX) 
was constructed, consisting of the lectin, EGF, SCR1, SCR2, 
transmembrane, and cytoplasmic domains of L-selectin,  as 
well as the extracellular membrane proximal domain of E-selec- 
tin (Fig.  1 A). 
Immunofluorescence microscopy (data  not  shown)  and 
FACS  |  analyses (Fig.  1 B)  indicated that the L-CDX chi- 
mera was expressed  on the cell surface of transfected ceils, 
and muhiple tranfection experiments revealed that L-CDX 
was consistently expressed at higher surface levels than wild- 
type L-selectin (Fig. 1 B). Proteolysis of L-selectin was evalu- 
ated by the presence or absence of L-selectin cleavage prod- 
ucts in metabolically labeled cell lysates and cell-free super- 
natants. We have previously shown that leukocytes and COS 
cells proteolyticaily cleave  the 74-kD membrane-bound  L-sdec- 
tin to form a 68-kD soluble fragment and a 6-kD transmem- 
brahe fragment (15). Antiserum JK564 directed against the 
L-sdectin cytoplasmic domain immunoprecipitated  the 74-kD 
cell surface form of L-selectin, as well as the 6-kD transmem- 
brane cleavage fragment from lysates of wild-type L-sdectin 
transfectants  (Fig.  1 C, lane 2). Antiserum JK923 directed 
against the ectodomain of L-sdectin immunoprecipitated  the 
68-kD soluble fragment of L-selectin from cell-free superna- 
tants of wild-type L-sdectin transfectants (Fig. 1 D, lane 2). 
Immunoprecipitation of lysates from L-CDX  transfectants 
with JK564 yielded large amounts of intact L-CDX; how- 
ever, the amount of the 6-kD transmembrane cleavage frag- 
ment was greatly reduced (Fig.  1 C,  lane 3).  In addition, 
cell-free supernatants of L-CDX immunoprecipitated with 
JK923 did not yield a detectable soluble 68-kD species (Fig. 
1 D, lane 3). To confirm these results, unlabeled cell-free su- 
pernatants were analyzed by a trapping ELISA to detect the 
released soluble L-selectin fragment. The amount of soluble 
L-selectin  detected in the supernatants of L-CDX transfec- 
rants was  •32-fold  less than that detected in the superna- 
tants of wild-type L-selectin  transfectants (Fig.  1 E). Both 
the  trapping  mAb  (DREG-55)  and  the  detecting mAb 
(DREG-200) recognize the L-CDX molecule expressed on 
Figure  2.  Point mutations of the cleavage site do not significantly in- 
hibit bselectin proteolysis. (A) Schematic representation  of the wild-type 
L-selectin cleavage domain and point mutations of the Lys321 and SCr322 
residues. The cleavage site is indicated with an inverted triangle. Nomen- 
clature for point mutations:  K321A indicates that the lysine at position 
321 has been mutated to an alanine; K321S/AA indicates that the lysine 
at position 321 and the adjacent serine residue at position  322 have both 
been mutated to alanine residues. (B) Mutation of the Pl or Pl' residues 
of the cleavage site to alanine has no affect on Irselectin proteolysis. COS 
cells were mock transfected or transfected with wild-type L-selectin  cDNA, 
K321A DNA, or $322A DNA, as indicated.  Cells were labeled and ana- 
lyzed as described in Fig. 1 C above. Cell lysates were immunoprecipitated 
with anticytoplasmic  domain serum.  The upper arrow denotes the posi- 
tion of the membrane-bound bselectin, and the lower arrow denotes the 
6-kD cleavage  product.  (C) Other mutations  of the bselectin cleavage  site. 
COS cells were transfected with wild-type l.-selectin cDNA or with mu- 
tant  DNA, as indicated,  and  analyzed as described above. 
the cell surface of transfectants (Fig. 1 B and data not shown). 
These data indicate that replacing the membrane-proximal 
cleavage  region of L-selectin with the corresponding  E-selectin 
domain effectively inhibited L-selectin  downregulation. In 
addition, the increased surface expression of L-CDX over that 
of wild-type L-selectin was consistent with a lack of proteol- 
ysis from the cell surface. 
Point Mutations of  the Cleavage Site Do Not Inhibit L-Selectin 
Downregulation.  L-selectin is cleaved between Lys 321 and 
Set 322 in both lymphoblasts and in L-selectin-transfected 
COS cells (15). To determine whether the Lys and Set at the 
P1 and Pl' positions of the cleavage site direct the specificity 
of cleavage, we mutated these amino acids to alanine. Clones 
K321A and $322A (Fig. 2 A) were expressed on the cell sur- 
face in amounts comparable with that of wild-type L-sdectin, 
as determined  by flow cytometry (data not shown). Antiserum 
directed against the cytoplasmic domain of L-sdectin immu- 
noprecipitated both the full-length cell surface form of the 
mutant L-sdectin, as well as a 6-kD transmembrane cleavage 
product (Fig. 2 B, lanes 3 and 4), indicating that the K321A 
and $322A  mutants are cleaved as efficiently  as wild-type 
L-sdectin (Fig.  2 B, lane 2). A  soluble form of L-selectin 
could be detected in the cell-free supernatant of K321A and 
$322A transfectants by immunoprecipitation  of radiolabded 
material and by ELISA assay of cold supernatants (data not 
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both the lysine and serine residues  to alanine (K321S/AA, 
Fig. 2 A) was also cleaved normally (Fig. 2 C, lane 7). Simi- 
larly, more radical point mutations that changed the net charge 
at the cleavage site by mutating the lysine or serine residues 
to glutamic acid (K321E  and $322E,  Fig.  2 C, lanes 4 and 
6) caused little change in L-selectin proteolysis. In all point 
mutations, the 6-kD transmembrane and the 68-kD soluble 
cleavage products were indistinguishable in size from the cor- 
responding fragments of wild-type L-selectin (Fig. 2 C), sug- 
gesting that the location of the cleavage site was not grossly 
altered.  These results indicate that proteolysis of L-sdectin 
from the surface of COS cells is not strictly dependent on 
the sequence  at the cleavage site. 
Mutations of  Conserved Amino Acids in the Membrane-proximal 
Cleavage Region Do Not Inhibit L-Selectin Downregulation.  The 
cleavage domain of L-selectin spans a 15-amino acid region 
that links the transmembrane domain and the last SCK do- 
main of  L-selectin. 10 of these amino acids are conserved across 
the rat, mouse, and human L-selectin sequences (Fig.  1 A), 
suggesting evolutionary pressure to maintain these sequences. 
To determine if these sequences contribute to a potential pro- 
tease docking site, these residues were mutated singly or in 
combination to alanine residues.  Mutants F323A,  $324A, 
I326A,  K327A,  Y331A,  S322FS/AAA,  and K327EGDY/ 
AAAAA  are illustrated in Fig. 3 A.  In addition, the glu- 
tamic acid residue at position 328 was mutated to glutamine 
(E328Q) to mimic an E-to-Q mutation found in a homolog- 
ous position of the/3-amyloid precursor protein from patients 
with Alzheimer's disease, Dutch type (32). The E-to-Q mu- 
tation in/3-APP prevents proteolysis at the normal membrane 
proximal site and results in aberrant processing leading to 
the formation of amyloid plaques.  All of the L-selectin mu- 
tants were expressed on the cell surface in amounts comparable 
with that of wild-type L-selectin (data not shown). Lysates 
of the single-point mutants yielded both the fuU-length cell 
surface form of the mutant L-selectin and the 6-kD trans- 
membrane cleavage product using  JK564 anticytoplasmic do- 
main serum (Fig. 3 B). Supernatants from each mutant also 
yielded a corresponding soluble 68-kD cleavage product when 
immunoprecipitated withJK923 antiectodomain serum (Fig. 
3 C). The 6-kD and 68-kD species immunoprecipitated from 
each mutant were indistinguishable in size from those im- 
munoprecipitated from wild-type L-selectin. 
A Ser-Phe-Ser  motif adjacent to the cleavage site is con- 
served across species, and a related motif is found proximal 
to the transmembrane domains of three proteins that are also 
cleaved from cell surfaces: ACE (33), CD16-II (34), and TNF 
receptor  II  (TNF-KII)  (35).  However, mutating all  three 
residues  to alanine (S322FS/AAA)  had no appreciable  effect 
on L-selectin proteolysis, as judged by the formation of the 
6-kD  transmembrane fragment (Fig.  2 C, lane 8)  and the 
68-kD soluble fragment (data not shown). Similarly, simul- 
Figure 3.  Mutagenesis  of conserved  residues within the cleavage  do- 
main do not affect  L-selectin  proteolysis.  (A) Schematic  representation  of 
point mutations  of conserved residues  within the L-selectifi  cleavage  do- 
main. Conserved  residues are shown as boxed sequences  in Fig. 1 A. (B) 
the 6-kD transmembrane  cleavage  product is detected  in lysates  of COS 
cells transfected  with point  mutations  of  conserved  cleavage  domain  residues. 
COS cells  were transfected  with wild-type  L-selectin  cDNA or with mu- 
tant DNA, as indicated,  and analyzed  as described  above.  The upper arrow 
denotes the position  of membrane-bound  L-selectin,  and the lower arrow 
denotes  position  of  the 6-kD cleavage  product. (C) Production  of  the soluble 
L-selectin  cleavage  product. Cell-free  supematants  were  harvested  from  trans- 
fectants and immunoprecipitated  with anti-L-selectin  ectodomain  serum. 
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Figure  4.  Short  deletions  within the cleavage  region  inhibit  L-selectin 
proteolysis.  (.'t) Schematic  representation  of the wild-type  L-selectin  cleavage 
domain and deletion  mutants. Nomenclature: K318AF323 indicates an 
inframe deletion that  joins K318 with F323. (B) The 6-kD transmem- 
brane cleavage  product is diminished  in lysates  of transfectants  expressing 
L-selectin  mutants  with deletions  of  four  to five  amino  acids  in the cleavage 
domain. COS cells were transfected  with wild-type  L-selectin  cDNA or 
with mutant DNA, as indicated, and analyzed  as in the legend to Fig. 
1. The upper arrow denotes  position of membrane-bound  L-selectin,  and 
the lower arrow denotes  the position of the 6-kD cleavage  product from 
wild-type transfectants. (C) Analysis  of the soluble bselectin cleavage 
product. Cell-free  superuatants  were  harvested  from  transfectants  and im- 
munoprecipitated with anti-L-selectin  ectodomain  serum. taneously mutating five conserved residues K327EGDY  to 
alanine  residues  (K327EGDY/AAAAA)  had no  affect on 
L-selectin proteolysis (see Fig. 5 A  and results below). The 
appearance of the 6-kD transmembrane species and the soluble 
68-kD species indicate that mutating conserved residues in 
the cleavage domain does not significantly inhibit the down- 
regulation of L-selectin. 
Short Deletions Within the Cleavage Domain Inhibit L-Selectin 
Proteolysis.  The E-selectin extracellular membrane-proximal 
region is eight amino acids shorter than the 15-amino acid 
L-selectin region (Fig. 1 A). In the L-CDX chimeric mole- 
cule, this difference in size may allow for steric or structural 
interference with L-selectin proteolysis.  We constructed a 
number of clones containing deletions  of four to five con- 
secutive amino acids in  the cleavage region to  determine 
whether truncating the native cleavage domain would affect 
L-selectin proteolysis. L-selectin deletion mutants are shown 
in Fig. 4 A and are characterized by deletions of four or five 
consecutive amino acids at various locations throughout the 
membrane-proximal cleavage  domain. Deletions spanning the 
cleavage site (K318AF323, L319AM325,  and D320AI326) 
significantly prevented L-selectin proteolysis, as demonstrated 
by the lack of 6-kD transmembrane (Fig. 4 B) or 68-kD soluble 
(Fig. 4 C) cleavage products.  The four-amino acid deletion 
(K318AF323) showed a small but detectable amount of the 
6-kD cleavage product (Fig. 4 B,  lane 3).  In contrast, the 
other five amino acid deletions showed no detectable 6-kD 
cleavage product. All deletion mutants showed no detectable 
amounts of the 68-kD soluble cleavage product in superna- 
tants of radiolabeled cells (Fig. 4 C). A low but measurable 
amount of soluble L-selectin could be detected by trapping 
ELISA in supernatants accumulated  over a course of 3 d (data 
not shown). The deletion mutants were expressed on the cell 
surface, as judged by immunoprecipitation of the intact cell 
surface form of the L-selectin deletion mutants radiolabeled 
cell lysates (Fig. 4 B,  upper arrow) and by immunofluores- 
cence microscopy. FACS  |  analysis of these cells indicated that 
the mean fluorescence of cells stained was higher for the de- 
letion mutants than for wild-type L-selectin (Table 1). To 
determine whether deletion of the actual cleavage site was 
necessary for inhibition of proteolysis, a five amino acid dele- 
Table  1.  Cell Surface Expression of the L-Selectin Deletion Mutants 
MFV* 
Mock  18.5 
L-setectin  147.0 
K318AF323  475.4 
L319AM325  451.4 
D320AI326  436.3 
I326AN332  401.7 
* Mean fluorescence  value of the total population. 
tion (I326AN332) of the COOH-terminal side of the cleavage 
domain was generated. This deletion mutant retains the na- 
tive cleavage site, yet L-selectin proteolysis was significantly 
inhibited (Fig. 4, B and C, lane 6). These data indicate that 
short deletions of the cleavage domain of L-selectin signifi- 
cantly inhibit proteolysis. This suggests that a minimal physical 
length of the cleavage domain may be important for accessi- 
bility to the site by the putative  protease. 
Restoring the Deleted Amino Acids in I326AN332 with Five 
Alanine Residues Restores L-Selectin Proteolysis.  The trunca- 
tion mutant I326AN332  retains the native cleavage site of 
L-selectin, yet it is not cleaved from the surface of transfected 
cells. To assess whether the native length and/or sequence 
of the cleavage domain were required for L-selectin proteol- 
ysis, we restored the five  deleted amino acids in the I326AN332 
mutant with five  alanine  residues (done K327EGDY/AAAAA, 
depicted in Fig. 3 A). FACS  |  analysis indicated that native 
L-selectin and K327EGDY/AAAAA transfectants have com- 
parable cell surface expression (data not shown). Restoration 
of the deletion with five alanine residues restores the ability 
of the mutant L-selectin to be cleaved. Immunoprecipitation 
of cell lysates of K327EGDY/AAAAA yielded a transmem- 
brane cleavage product that migrated slightly faster than the 
wild-type cleavage product (Fig. 5 A, compare lanes 2 and 
3). Cell-free supernatants immunoprecipitated with antiserum 
directed against the extracellular domain of L-selectin showed 
the expected 68-kD  soluble cleavage product (Fig. 5 B). In 
contrast,  the original deletion mutant I326AN332  showed 
no detectable 6-kD transmembrane or 68-kD soluble cleavage 
products (Fig. 5, A  and B,  lane 1). 
Since the  6-kD  cleavage product  of the  K327EGDY/ 
AAAAA migrated faster than the native cleavage product, 
we used radiochemical sequence analysis to determine if the 
deavage site was shifted. We have previously shown that the 
6-kD cleavage product of wild-type L-selectin transfectants 
metabolically labeled with [3SS]methionine  yields radioactive 
methionine peaks at cycles 4 and 20, indicating cleavage be- 
tween Lys321 and Ser322 (15). The cleavage site was verified 
by radiochemical sequencing of cells labeled with [3H]phe- 
nylalanine and other tritiated amino acids (reference 15 and 
data not shown). Radiochemical sequence  analysis  of the 6-kD 
product from [35S]methionine-labeled  K327EGDY/AAAAA 
mutant also yielded peaks at cycles  4 and 20 (Fig. 5 C), indi- 
cating that cleavage occurs at the native site between Lys321 
and Ser322. The apparent size difference of the K327EGDY/ 
AAAAA mutant 6-kD product may be a result of anoma- 
lous migration of the small alanine-rich peptide in gel elec- 
trophoresis. 
These results indicate that restoring the native length, but 
not the native sequence, of the L-selectin cleavage region re- 
stores L-selectin proteolysis. In addition,  L-selectin proteol- 
ysis occurs at the native cleavage site, between Lys321 and 
Ser322, despite the five-residue mutation. These data may 
suggest that L-selectin proteolysis occurs at a defined length 
from the membrane and further support  the model that 
L-selectin proteolysis may depend on the physical length, but 
not necessarily the sequence, of the cleavage domain. 
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L-selectin downregulation involves an unusual  and yet- 
unknown  proteolytic  mechanism.  Most  proteases  can  be 
classified into one of four basic protease families- serine pro- 
tease, metalloprotease,  aspartic protease, or cysteine protease- 
based on their inhibition by specific mechanism-based pro- 
tease inhibitors (36).  However, previous studies have shown 
that broad panels of common protease inhibitors have no effect 
on L-selectin proteolysis (reference 18 and unpublished ob- 
servations).  Moreover, most proteases also  show some de- 
gree of sequence specificity in the Pl or Pl' positions of the 
cleavage site (36). We have previously shown that the cleavage 
event occurs between Lys321 and Ser322  in a short region 
that links the last SCR with the transmembrane domain (15). 
In this report we demonstrate further that L-selectin proteoly- 
sis is remarkably resilient to point mutations of the cleavage 
site. The lysine at the Pl position is suggestive of a possible 
trypsinlike specificity, yet a mutation that radically changes 
the net charge of the Pl position from a basic lysine residue 
to an acidic glutamic acid is still efficiently cleaved.  10 of 11 
amino acid residues downstream of the cleavage site are con- 
served across mouse, rat, and human L-selectin (21-26, 37), 
suggesting a possible  conserved protease docking site. The 
$322FS motif was of particular interest, since a related motif 
is found proximal to the transmembrane domains of other 
cleaved membrane proteins, such as ACE (33), CD16-II(34), 
and TNF receptor type II (35).  However, mutation of the 
SFS motif to three alanine residues had no dramatic effect 
on L-selectin proteolysis. Similarly, alanine scanning muta- 
genesis of other conserved residues showed no strict sequence 
requirement for L-selectin proteolysis. In contrast, short de- 
letions within the cleavage domain have a dramatic impact 
on L-selectin proteolysis. The I326AN332  deletion mutant 
retains the native cleavage site but is not effectively cleaved 
from the cell surface. Restoration of the deleted amino acids 
with five alanine residues restores L-selectin proteolysis. These 
results suggest that the proteolytic cleavage of L-selectin ap- 
pears  to have a relaxed sequence specificity at  the cleavage 
site, but that a minimal physical length of the cleavage do- 
main may be important for the accessibility to  the site by 
the putative protease. 
The apparent relaxed sequence specificity of the cleavage 
site is reminiscent of that described for several other cell sur- 
face molecules that are known to undergo membrane-proximal 
proteolysis. Membrane-anchored precursors of growth factors, 
such as TGF-o6 EGF,  CSF-1, TNF-c~, and the c-kit ligand, 
are cleaved to release a soluble form of growth factor (38, 
39). The cleavage region of TGF-o~ and TNF-o~ must be ex- 
tensively mutated to inhibit proteolysis (39-41).  However, 
the protease activity involved in cleaving these membrane- 
anchored growth factors shows specificity for small aliphatic 
residues,  such as alanine and valine, and can be inhibited by 
serine protease inhibitors  (39).  Other proteins  such as the 
B-amyloid precursor protein  (~-APP)  (42,  43),  the folate 
receptor (44), TNF receptor (35, 45), IL-6 receptor (46), and 
ACE (47) are also released from cell membranes by a regu- 
lated proteolytic mechanism. The proteolysis of ACE (47), 
IL-6 receptor (46),  and the TNF receptor (45),  like that of 
L-sdectin, appears  resistant to a broad panel of protease in- 
hibitors. Interestingly, rabbit ACE is deaved between an ar- 
ginine and a serine residue (47), and B-APP (42, 43), is cleaved 
between a lysine and a leucine residue. These cleavage sites 
are homologous to the lysine and serine residues at the Pl 
and Pl' positions, respectively, of the L-selectin cleavage site. 
Also, like L-selectin, these other receptors are cleaved when 
expressed in COS or Chinese hamster ovary cells,  and the 
cleavage specificity is retained (42, 43, 46, 47). Despite the 
apparent similarity of these cleavage sites, the cleavage regions 
of/3-APP, ACE, and L-selectin can be mutated without dra- 
matic effect on the efficiency of proteolysis. Moreover, large 
deletions in the membrane proximal cleavage regions of B-APP 
and ACE have no affect on their proteolysis (42).  Cryptic 
cleavage sites in upstream sequences of ~-APP are activated; 
however, cleavage occurs at a similar distance from the trans- 
membrane domain as found in the native cleavage site, sug- 
gesting that the physical distance from the membrane is crit- 
ical.  In contrast,  small deletions in the L-selectin cleavage 
region have a profound affect on L-sdectin proteolysis. It is 
possible that the cysteine residue at position 316 of L-sdectin, 
which contributes to  an intrachain disulfide bridge in the 
second SCR, may allow for steric or structural interference 
with the protease and prevent cleavage at upstream sequences. 
Figure 5.  Restoration  of the I326AN332  dele- 
tion with five alanine residues also restores suscepti- 
bility to proteolysis. The five amino acid residues 
deleted in the I326AN332  mutation were replaced 
with five  alanine  residues. COS cells  were mock trans- 
fected,  transfected  with wild-type L-selectin, the 
I326AN332 deletion mutant, or the restored K327- 
EGDY/AAAAA mutant, as indicated. (A) Cell ly- 
sates were analyzed  for the presence  of the 6-kD trans- 
membrane  cleavage product,  and  (B)  cell-free 
supernatants were analyzed for the presence of the 
soluble l~selectin  cleavage  fragment. (C) The K327- 
EGDY/AAAAA mutant is cleaved  between Lys 321 
and Set  322.  The 6-kD transmembrane cleavage 
product  was isolated from [3SS]methionine-labeled 
transfectants subjected to SDS-PAGE  and transferred 
to polyvinyldifluoride membrane. The 6-kD band was visualized by autoradiography, excised, and subjected to a pulse-liquid protein sequencer. Assign- 
ment of methionine residues was made based on radioactive peak fractions and aligned to the cleavage region of L-selectin, as described previously (15). 
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not direct proteolysis, then the protease must use some other 
docking site or other means of recognizing its substrate.  In 
the case of TGF-c~, Bosenberg et al. (48) elegantly demon- 
strated that the COOH-terminal valine of the cytoplasmic 
domain was required for proteolysis at the extracellularjuxta- 
membranous site. However, this is not likely to be a universal 
theme for all cleaved proteins, since cytoplasmic tail trunca- 
tion of the TNF receptor does not affect its proteolytic re- 
lease from the cell membrane. Similarly, we have found that 
truncation of the last five residues of the cytoplasmic tail of 
L-selectin does not prevent proteolysis, however,  the cyto- 
plasmic tail may influence the efficiency of proteolysis (Kahn, 
J., and T. K. Kishimoto, unpublished observations).  Under- 
standing how a protease recognizes L-selectin as a substrate 
may provide a handle for identifying a putative protease.  It 
is worth noting that a physiologically relevant protease  has 
not been identified in the case of any protein that undergoes 
regulated membrane-proximal proteolysis. If a common pro- 
teolytic mechanism exists, then identification of such a pro- 
tease could provide important insight into the regulation of 
inflammation (bselectin, TNF receptor), hypertension (ACE), 
or the pathogenesis of Alzheimer's disease (~-APP). 
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